May 05, 2022
The Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Colorado, revealed a variety of advancements in technology, pivotal trials and clinical trial design.
May 02, 2022
The study found no association between treatment and the risk of chronic kidney disease or end-stage renal disease.
May 01, 2022
The axitinib intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.
March 31, 2022
If the Biologics License Application is approved by the FDA, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.
March 22, 2022
The implant achieves impressive efficacy and reduces treatment burden.
March 18, 2022
Taiichi Hikichi, MD, counteracted the potential inflammatory effect of brolucizumab by combining its administration with a sub-Tenon’s capsule injection of triamcinolone acetonide.
March 16, 2022
Firas M. Rahhal, MD, discusses concerns of using repackaged IV bevacizumab for the treatment of wet AMD.
March 14, 2022
The first FDA-approved bispecific antibody for the eye targets two leading causes of vision loss.
March 08, 2022
Reducing the treatment burden is a prime goal for emerging AMD therapies.
February 27, 2022
KSI-301, a therapy for patients with nAMD, did not meet the primary endpoint of showing non-inferior visual acuity gains compared to aflibercept given every eight weeks; however, it was safe and well-tolerated with no new or unexpected safety signals.
